Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Short Interest Up 95.9% in June

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the recipient of a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 65,485 shares, an increase of 95.9% from the May 31st total of 33,421 shares. Based on an average daily volume of 64,658 shares, the short-interest ratio is presently 1.0 days. Currently, 0.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Nanobiotix

Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares during the period. Marshall Wace LLP acquired a new stake in Nanobiotix in the fourth quarter valued at approximately $220,000. Finally, Millennium Management LLC acquired a new stake in Nanobiotix in the fourth quarter valued at approximately $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on NBTX. Guggenheim upped their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. Leerink Partners boosted their price objective on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. UBS Group raised their target price on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Finally, TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Nanobiotix currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.33.

Nanobiotix Stock Performance

NASDAQ NBTX traded up $1.76 during mid-day trading on Wednesday, reaching $39.46. 63,774 shares of the stock were exchanged, compared to its average volume of 62,758. The business’s 50 day moving average is $38.67 and its 200-day moving average is $30.72. Nanobiotix has a 1 year low of $4.73 and a 1 year high of $57.14.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $3.42 million for the quarter. On average, research analysts predict that Nanobiotix will post 0.19 earnings per share for the current year.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.